Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-26T13:48:09.120Z Has data issue: false hasContentIssue false

10 - IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS

Published online by Cambridge University Press:  11 July 2009

S. Vincent Rajkumar
Affiliation:
Mayo Clinic, Minnesota
Robert A. Kyle
Affiliation:
Mayo Clinic, Minnesota
Get access

Summary

INTRODUCTION

For over 90 years, amyloidosis has been defined by its tinctorial properties. Any histologic tissue section that binds the cotton wool dye Congo red and demonstrates green birefringence when viewed under polarized light is, by definition, an amyloid deposit, and the patient with this deposit has amyloidosis. Refinements of the original Congo red stain include the alkaline Congo red technique of including the use of permanganate and performate pretreatment to enhance the sensitivity of the test. Congo red fluorescence has been introduced to detect small amyloid deposits that would be missed with traditional staining. Phenol Congo red staining has been suggested to enhance the sensitivity of the traditional Congo red study.

All amyloid deposits are amorphous under the light microscope and appear pink with standard hematoxylin and eosin staining. With electron microscopy, amyloid is not amorphous but represents nonbranching fibrils that are composed of protofilaments that are wound into the fibril. The width of the fibril is approximately 10 nm. Amyloid is insoluble in aqueous solution, and repeated homogenizations that discard the supernatant have been used for 40 years to purify amyloid deposits. The resulting pellet, when suspended in distilled water, contains relatively pure amyloid fibrils that can then be separated by high-performance liquid chromatography and sequenced.

CLASSIFICATION

When amyloidosis was first described in the latter half of the 19th century, biochemical composition and ultrastructure of the amyloid deposit was unknown. The disease was, therefore, classified into three categories.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bely, M, Makovitzky, J.Sensitivity and specificity of Congo red staining according to Romhanyi. Comparison with Puchtler's or Bennhold's methods. Acta Histochem 2006;108:175–80.CrossRefGoogle ScholarPubMed
Puchtler, H, Sweat, F.Congo red as a stain for fluorescence microscopy of amyloid. J Histochem Cytochem 1965;13:693–4.CrossRefGoogle ScholarPubMed
Ishii, W, Matsuda, M, Nakamura, N, et al. Phenol Congo red staining enhances the diagnostic value of abdominal fat aspiration biopsy in reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med 2003;42:400–5.CrossRefGoogle ScholarPubMed
Pras, M, Schubert, M, Zucker-Franklin, D, Rimon, A, Franklin, EC.The characterization of soluble amyloid prepared in water. J Clin Invest 1968;47:924–33.Google ScholarPubMed
Benson, MD.Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid 2005;12:75–87.CrossRefGoogle ScholarPubMed
Sipe, JD, Cohen, AS.Review: history of the amyloid fibril. J Struct Biol 2000;130:88–98.CrossRefGoogle ScholarPubMed
Peng, S, Glennert, J, Westermark, P.Medin-amyloid: a recently characterized age-associated arterial amyloid form affects mainly arteries in the upper part of the body. Amyloid 2005;12:96–102.CrossRefGoogle Scholar
Rocken, C, Shakespeare, A.Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002;440:111–22.CrossRefGoogle ScholarPubMed
Hilst, JC, Simon, A, Drenth, JP.Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005;5:87–98.CrossRefGoogle ScholarPubMed
Pepys, MB.Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci 2001;356:203–10; discussion 210–11.CrossRefGoogle ScholarPubMed
Pokkuluri, PR, Solomon, A, Weiss, DT, Stevens, FJ, Schiffer, M.Tertiary structure of human lambda 6 light chains. Amyloid 1999;6:165–71.CrossRefGoogle ScholarPubMed
Solomon, A, Weiss, DT, Pepys, MB.Induction in mice of human light-chain-associated amyloidosis. Am J Pathol 1992;140:629–37.Google ScholarPubMed
Rajkumar, SV, Dispenzieri, A, Kyle, RA.Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006;81:693–703.CrossRefGoogle ScholarPubMed
Rajkumar, SV, Gertz, MA, Kyle, RA.Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998;82:1501–5.3.0.CO;2-8>CrossRefGoogle ScholarPubMed
Kyle, RA, Linos, A, Beard, CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992;79:1817–22.Google ScholarPubMed
Palladini, G, Perfetti, V, Merlini, G.Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly 2006;136:715–20.Google ScholarPubMed
Park, MA, Mueller, PS, Kyle, RA, Larson, DR, Plevak, MF, Gertz, MA.Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore) 2003; 82:291–8.CrossRefGoogle ScholarPubMed
Shah, KB, Inoue, Y, Mehra, MR.Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006;166:1805–13.CrossRefGoogle ScholarPubMed
Rodriguez, RJ, Iglesias, CG, Rubin, J.Primary amyloidosis and syncope. Int J Cardiol 1997;58:185–7.Google Scholar
Pan, WH, Li, NP.Clinical pathological feature of early tongue amyloidosis. Chin Med Sci J 2006;21:104–6.Google ScholarPubMed
Gertz, MA, Kyle, RA, Griffing, WL, Hunder, GG.Jaw claudication in primary systemic amyloidosis. Medicine (Baltimore) 1986;65:173–9.CrossRefGoogle ScholarPubMed
Ing, EB, Woolf, IZ, Younge, BR, Bjornsson, J, Leavitt, JA.Systemic amyloidosis with temporal artery involvement mimicking temporal arteritis. Ophthalmic Surg Lasers 1997;28:328–31.Google ScholarPubMed
Guerreiro, Moura CG, Pinto, Souza S.Images in clinical medicine. “Shoulder pad” sign. N Engl J Med 2004;351:e23.Google Scholar
Jardinet, D, Westhovens, R, Peeters, J.Sicca syndrome as an initial symptom of amyloidosis. Clin Rheumatol 1998;17:546–8.CrossRefGoogle ScholarPubMed
Hasserjian, RP, Goodman, HJ, Lachmann, HJ, Muzikansky, A, Hawkins, PN.Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients. Histopathology 2007;50:567–73.CrossRefGoogle ScholarPubMed
Picken, MM, Herrera, GA.The burden of “sticky” amyloid: typing challenges. Arch Pathol Lab Med 2007;131:850–1.Google ScholarPubMed
Comenzo, RL, Zhou, P, Fleisher, M, Clark, B, Teruya-Feldstein, J.Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006;107:3489–91.CrossRefGoogle Scholar
Neben-Wittich, MA, Foote, RL, Kalra, S.External beam radiation therapy for tracheobronchial amyloidosis. Chest 2007;132:262–7.CrossRefGoogle ScholarPubMed
Gaurav, K, Panda, M.An uncommon cause of bilateral pulmonary nodules in a long-term smoker. J Gen Intern Med 2007;22:1617–20.CrossRefGoogle Scholar
Lesslauer, W.On the structure of agglutinated sheep red blood cell membranes. Biochim Biophys Acta 1976;436:25–37.CrossRefGoogle ScholarPubMed
Lachmann, HJ, Goodman, HJ, Gilbertson, JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361–71.CrossRefGoogle ScholarPubMed
Moon, WK, Kim, SH, Im, JG, Yeon, KM, Han, MC.Castleman disease with renal amyloidosis: imaging findings and clinical significance. Abdom Imaging 1995;20:376–8.CrossRefGoogle ScholarPubMed
Hou, X, Aguilar, MI, Small, DH.Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 2007;274:1637–50.CrossRefGoogle ScholarPubMed
Granel, B, Valleix, S, Serratrice, J, et al.. Lysozyme amyloidosis: report of 4 cases and a review of the literatureMedicine (Baltimore) 2006;85:66–73.CrossRefGoogle Scholar
Lachmann, HJ, Booth, DR, Booth, SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786–91.CrossRefGoogle ScholarPubMed
Ng, B, Connors, LH, Davidoff, R, Skinner, M, Falk, RH.Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425–29.CrossRefGoogle ScholarPubMed
Kyle, RA, Spittell, PC, Gertz, MA, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996;101:395–400.CrossRefGoogle ScholarPubMed
Kyle, RA, Gertz, MA.Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59.Google ScholarPubMed
Morris, KL, Tate, JR, Gill, D, et al. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Intern Med J 2007;37:456–63.CrossRefGoogle ScholarPubMed
Abraham, RS, Katzmann, JA, Clark, RJ, Bradwell, AR, Kyle, RA, Gertz, MA.Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119:274–8.CrossRefGoogle ScholarPubMed
Leung, N, Dispenzieri, A, Lacy, MQ, et al. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol 2007;2:440–4.CrossRefGoogle ScholarPubMed
Mayo, MM, Johns, GS.Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias. Contrib Nephrol 2007;153:44–65.CrossRefGoogle ScholarPubMed
Dispenzieri, A, Lacy, MQ, Katzmann, JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006;107:3378–83.CrossRefGoogle ScholarPubMed
Akar, H, Seldin, DC, Magnani, B, et al. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid 2005;12:210–15.CrossRefGoogle ScholarPubMed
Hazenberg, BP, Rijswijk, MH, Lub-De Hooge, MN, et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 2007;48:865–72.CrossRef
Lechapt-Zalcman, E, Authier, FJ, Creange, A, Voisin, MC, Gherardi, RK.Labial salivary gland biopsy for diagnosis of amyloid polyneuropathy. Muscle Nerve 1999;22:105–7.3.0.CO;2-O>CrossRefGoogle ScholarPubMed
Yoshimatsu, S, Ando, Y, Terazaki, H, et al. Endoscopic and pathological manifestations of the gastrointestinal tract in familial amyloidotic polyneuropathy type I (Met30). J Intern Med 1998;243:65–72.CrossRefGoogle Scholar
Guy, CD, Jones, CK.Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol 2001;24:181–5.3.0.CO;2-D>CrossRefGoogle ScholarPubMed
Olsen, KE, Sletten, K, Westermark, P.The use of subcutaneous fat tissue for amyloid typing by enzyme-linked immunosorbent assay. Am J Clin Pathol 1999;111:355–62.Google ScholarPubMed
Palladini, G, Malamani, G, Co, F, et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 2001;24:1228–33.CrossRefGoogle ScholarPubMed
Lindqvist, P, Olofsson, BO, Backman, C, Suhr, O, Waldenstrom, A.Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiogr 2006;7:22–30.CrossRefGoogle ScholarPubMed
Bellavia, D, Abraham, TP, Pellikka, PA, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr 2007;20:1194–202.CrossRefGoogle ScholarPubMed
Dispenzieri, A, Gertz, MA, Kyle, RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–7.CrossRefGoogle ScholarPubMed
Dispenzieri, A, Gertz, MA, Kyle, RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104:1881–7.CrossRefGoogle ScholarPubMed
Zerbini, CA, Anderson, JJ, Kane, KA, et al. Beta 2 microglobulin serum levels and prediction of survival in AL amyloidosis. Amyloid 2002;9:242–6.CrossRefGoogle ScholarPubMed
Gertz, MA, Lacy, MQ, Dispenzieri, A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007;92:1415–18.b.CrossRefGoogle ScholarPubMed
Caccialanza, R, Palladini, G, Klersy, C, et al. Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. Am J Clin Nutr 2006;83:350–4.CrossRefGoogle ScholarPubMed
Gertz, MA, Comenzo, R, Falk, RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005;79:319–28.CrossRefGoogle ScholarPubMed
Sanchorawala, V.Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol 2006;1:1331–41.CrossRefGoogle ScholarPubMed
Mukai, S, Lipsitz, LA.Orthostatic hypotension. Clin Geriatr Med 2002;18:253–68.CrossRefGoogle ScholarPubMed
Gillmore, JD, Goodman, HJ, Lachmann, HJ, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006;107:1227–9.CrossRefGoogle ScholarPubMed
Gertz, MA, Kyle, RA, O'Fallon, WM.Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Arch Intern Med 1992;152:2245–50.CrossRefGoogle ScholarPubMed
Leung, N, Griffin, MD, Dispenzieri, A, et al. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 2005;5:1660–70.CrossRefGoogle ScholarPubMed
Gillmore, JD, Madhoo, S, Pepys, MB, Hawkins, PN.Renal transplantation for amyloid end-stage renal failure – insights from serial serum amyloid P component scintigraphy. Nucl Med Commun 2000;21:735–40.CrossRefGoogle ScholarPubMed
Lacy, MQ, Dispenzieri, A, Hayman, SR, et al. Sequential heart and autologous stem cell transplantation for AL amyloidosis (Abstract 3092). Blood (ASH Annual Meeting Abstracts) 2006;108:3092.Google Scholar
Kyle, RA, Gertz, MA, Greipp, PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202–7.CrossRefGoogle ScholarPubMed
Dhodapkar, MV, Jagannath, S, Vesole, D, et al. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma 1997;27:351–6.CrossRefGoogle ScholarPubMed
Gertz, MA, Lacy, MQ, Lust, JA, Greipp, PR, Witzig, TE, Kyle, RA.Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Am J Hematol 1999;61:115–19.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
Gertz, MA, Lacy, MQ, Lust, JA, Greipp, PR, Witzig, TE, Kyle, RA.Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 1999;16:104–9.CrossRefGoogle ScholarPubMed
Palladini, G, Anesi, E, Perfetti, V, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001;113:1044–6.CrossRefGoogle ScholarPubMed
Dhodapkar, MV, Hussein, MA, Rasmussen, E, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004;104:3520–6.CrossRefGoogle Scholar
Palladini, G, Perfetti, V, Obici, L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936–8.CrossRefGoogle ScholarPubMed
Palladini, G, Russo, P, Nuvolone, M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007;110:787–8.CrossRefGoogle ScholarPubMed
Seldin, DC, Choufani, EB, Dember, LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003;3:241–6.CrossRefGoogle ScholarPubMed
Dispenzieri, A, Lacy, MQ, Rajkumar, SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003;10:257–61.CrossRefGoogle ScholarPubMed
Palladini, G, Perfetti, V, Perlini, S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005;105:2949–51.CrossRefGoogle Scholar
Sanchorawala, V, Wright, DG, Rosenzweig, M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109:492–6.CrossRefGoogle ScholarPubMed
Dispenzieri, A, Lacy, MQ, Zeldenrust, SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465–70.CrossRefGoogle ScholarPubMed
Wechalekar, AD, Gillmore, JD, Lachmann, HJ, Offer, M, Hawkins, PN.Efficacy and safety of bortezomib in systemic AL amyloidosis – a preliminary report (Abstract). Blood (ASH Annual Meeting Abstracts) 2006;108:29.Google Scholar
Reece, , Sanchorawala, V, Hegenbart, U, et al. Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL) (Abstract 8050). J Clin Oncol (Meeting Abstracts) 2006;25:8050.Google Scholar
Kastritis, E, Anagnostopoulos, A, Roussou, M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351–8.CrossRefGoogle ScholarPubMed
Gertz, MA, Lacy, MQ, Dispenzieri, A, Hayman, SR, Kumar, S.Transplantation for amyloidosis. Curr Opin Oncol 2007;19: 136–41.CrossRefGoogle ScholarPubMed
Gertz, MA, Lacy, MQ, Dispenzieri, A, Hayman, SR.Amyloidosis. Best Pract Res Clin Haematol 2005;18:709–27.CrossRefGoogle ScholarPubMed
Sanchorawala, V, Wright, DG, Seldin, DC, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004;33:381–8.CrossRefGoogle ScholarPubMed
Comenzo, RL, Sanchorawala, V, Fisher, C, et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999;104:553–9.CrossRefGoogle ScholarPubMed
Gertz, MA, Lacy, MQ, Dispenzieri, A, et al. Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). Bone Marrow Transplant 2007;40:989–3.CrossRefGoogle Scholar
Gertz, MA, Lacy, MQ, Dispenzieri, A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025–31.CrossRefGoogle ScholarPubMed
Cohen, AD, Zhou, P, Chou, J, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007;139:224–33.CrossRefGoogle Scholar
Vesole, DH, Perez, WS, Akasheh, M, Boudreau, C, Reece, , Bredeson, CN.High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006;81:880–8.CrossRefGoogle ScholarPubMed
Gertz, MA, Blood, E, Vesole, DH, Abonour, R, Lazarus, HM, Greipp, PR.A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant 2004;34:149–54.CrossRefGoogle ScholarPubMed
Jaccard, A, Moreau, P, Leblond, V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083–93.CrossRefGoogle ScholarPubMed
Dispenzieri, A, Kyle, RA, Lacy, MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004;103:3960–3.CrossRefGoogle ScholarPubMed
Porrata, LF, Gertz, MA, Litzow, MR, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005;11:1210–18.Google ScholarPubMed
Leung, N, Leung, TR, Cha, SS, Dispenzieri, A, Lacy, MQ, Gertz, MA.Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 2005;106:3353–7.CrossRefGoogle ScholarPubMed
Leung, N, Dispenzieri, A, Fervenza, FC, et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis 2005;46:270–7.CrossRefGoogle ScholarPubMed
Seldin, DC, Anderson, JJ, Sanchorawala, V, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004;104:1888–93.CrossRefGoogle ScholarPubMed
Schonland, SO, Perz, JB, Hundemer, M, et al. Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation 2005;80:S160–3.CrossRefGoogle ScholarPubMed
Sanchorawala, V, Wright, DG, Quillen, K, et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant 2007;40:607.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×